NASDAQ:GALT - Galectin Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$5.12 +0.15 (+3.02 %)
(As of 02/19/2019 01:19 AM ET)
Previous Close$4.97
Today's Range$4.83 - $5.12
52-Week Range$3.10 - $9.49
Volume613,541 shs
Average Volume259,997 shs
Market Capitalization$210.62 million
P/E Ratio-10.45
Dividend YieldN/A
Beta3.76
Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease, skin disease, and cancer. The company's lead product candidate includes galectin-3 inhibitor (GR-MD-02), a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., is also involved in the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics, Inc. was founded in 2000 and is based in Norcross, Georgia.

Receive GALT News and Ratings via Email

Sign-up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GALT
CUSIPN/A
Phone678-620-3186

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.22) per share

Profitability

Net Income$-16,230,000.00

Miscellaneous

Employees7
Market Cap$210.62 million
OptionableOptionable

Galectin Therapeutics (NASDAQ:GALT) Frequently Asked Questions

What is Galectin Therapeutics' stock symbol?

Galectin Therapeutics trades on the NASDAQ under the ticker symbol "GALT."

How were Galectin Therapeutics' earnings last quarter?

Galectin Therapeutics Inc. (NASDAQ:GALT) announced its quarterly earnings data on Tuesday, November, 13th. The company reported ($0.07) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.09) by $0.02. View Galectin Therapeutics' Earnings History.

When is Galectin Therapeutics' next earnings date?

Galectin Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, April 4th 2019. View Earnings Estimates for Galectin Therapeutics.

What price target have analysts set for GALT?

2 brokerages have issued 12 month price targets for Galectin Therapeutics' shares. Their predictions range from $11.00 to $12.00. On average, they expect Galectin Therapeutics' share price to reach $11.50 in the next twelve months. This suggests a possible upside of 124.6% from the stock's current price. View Analyst Price Targets for Galectin Therapeutics.

What is the consensus analysts' recommendation for Galectin Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galectin Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Galectin Therapeutics.

Has Galectin Therapeutics been receiving favorable news coverage?

Headlines about GALT stock have trended positive on Tuesday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Galectin Therapeutics earned a media sentiment score of 2.3 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the stock's share price in the immediate future.

Who are some of Galectin Therapeutics' key competitors?

Who are Galectin Therapeutics' key executives?

Galectin Therapeutics' management team includes the folowing people:
  • Dr. Harold H. Shlevin, Pres & CEO (Age 69)
  • Mr. Jack W. Callicutt, Chief Financial Officer (Age 52)
  • Robert Tritt, Gen. Counsel
  • Dr. Eliezer Zomer, Exec. VP of Manufacturing & Product Devel. (Age 72)
  • Mr. J. Rex Horton, Exec. Director of Regulatory Affairs & Quality Assurance (Age 49)

Who are Galectin Therapeutics' major shareholders?

Galectin Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include D.A. Davidson & CO. (1.75%), Advisor Group Inc. (1.64%), BlackRock Inc. (1.47%), Geode Capital Management LLC (0.55%), Barclays PLC (0.42%) and BT Wealth Management LLC (0.12%). Company insiders that own Galectin Therapeutics stock include Fund LP 10X, Gilbert F Amelio, Gilbert S Omenn, Harold H Shlevin, Jack W Callicutt, James C Czirr, Joel Lewis, Kary Eldred, Kevin D Freeman, Marc Rubin, Peter G Traber, Richard E Uihlein and Theodore Daniel Zucconi. View Institutional Ownership Trends for Galectin Therapeutics.

Which institutional investors are selling Galectin Therapeutics stock?

GALT stock was sold by a variety of institutional investors in the last quarter, including First Foundation Advisors and Cetera Advisor Networks LLC. Company insiders that have sold Galectin Therapeutics company stock in the last year include Fund LP 10X, Gilbert F Amelio, Gilbert S Omenn, Harold H Shlevin, Jack W Callicutt, James C Czirr, Marc Rubin, Peter G Traber and Theodore Daniel Zucconi. View Insider Buying and Selling for Galectin Therapeutics.

Which institutional investors are buying Galectin Therapeutics stock?

GALT stock was bought by a variety of institutional investors in the last quarter, including Barclays PLC, Advisor Group Inc., BT Wealth Management LLC, D.A. Davidson & CO., Geode Capital Management LLC, Stratos Wealth Partners LTD., MML Investors Services LLC and BlackRock Inc.. Company insiders that have bought Galectin Therapeutics stock in the last two years include Joel Lewis, Kary Eldred, Kevin D Freeman, Marc Rubin, Richard E Uihlein and Theodore Daniel Zucconi. View Insider Buying and Selling for Galectin Therapeutics.

How do I buy shares of Galectin Therapeutics?

Shares of GALT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Galectin Therapeutics' stock price today?

One share of GALT stock can currently be purchased for approximately $5.12.

How big of a company is Galectin Therapeutics?

Galectin Therapeutics has a market capitalization of $210.62 million. The company earns $-16,230,000.00 in net income (profit) each year or ($0.49) on an earnings per share basis. Galectin Therapeutics employs 7 workers across the globe.

What is Galectin Therapeutics' official website?

The official website for Galectin Therapeutics is http://www.galectintherapeutics.com.

How can I contact Galectin Therapeutics?

Galectin Therapeutics' mailing address is 4960 PEACHTREE INDUSTRIAL BLVD. SUITE 240, NORCROSS GA, 30071. The company can be reached via phone at 678-620-3186 or via email at [email protected]


MarketBeat Community Rating for Galectin Therapeutics (NASDAQ GALT)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  251 (Vote Outperform)
Underperform Votes:  209 (Vote Underperform)
Total Votes:  460
MarketBeat's community ratings are surveys of what our community members think about Galectin Therapeutics and other stocks. Vote "Outperform" if you believe GALT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GALT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel